Investors & Media Press Releases
Axovant Announces First Parkinson's Disease Gene Therapy R&D Day and Participation in Upcoming September Conferences"
- Parkinson’s Disease R&D Day to be hosted by
Investor and Patient Conference Presentation details:
|2020 Virtual GM1 Family Meeting|
|AXO-Lenti-PD Parkinson’s Disease R&D Day|
|Additional details to be provided later in September.|
A live webcast of the presentations will be available in the Events section of
About Axovant Gene Therapies
Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates target GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinson’s disease.
Media & Investors
Source: Axovant Gene Therapies